88IV - PR Newswire Asia's news - Biotechnology

< Previous page

| Title only | Print

Next page >

Boostimmune Secures Japanese Patent for Sequence-Independent TCTP Antibody Technology Targeting MDSC Accumulation Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulation of MDSCs in the tumor microenvironment Granted claims are not expressly ... 2026-07-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB SHANGHAI and HONG KONG , July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited (" Antengene ", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated ... 2026-07-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases SHANGHAI , July 13, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical ... 2026-07-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC NANJING, China , July 10, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license ... 2026-07-10T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026 CAMBRIDGE, Mass. , July 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech ... 2026-07-09T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo HANGZHOU, China, SHANGHAI and BOSTON , July 9, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on ... 2026-07-09T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations SAN DIEGO, July 9, 2026 /PRNewswire/ -- On the eve of the highly anticipated BIO International Convention 2026, the BIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. ... 2026-07-09T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026 MONTPELLIER, France , July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading ... 2026-07-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) Included in the MSCI ESG Selection Indexes for the fourth consecutive year Leader in ... 2026-07-08T Biotechnology Environmental Products & Services Health Care/Hospital Medical/Pharmaceuticals
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects ... 2026-07-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved